source
- Merck halts development of BTK inhibitor nemtabrutinib after safety concernsMerck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
- FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drugThe U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…